# Martin Heidecker > Martin Heidecker is a Series A investor at Boehringer Ingelheim Venture Fund backing Biotechnology. See 10 investments, check sizes, portfolio. Updated Aug… - Type: Angel Investor - Fund: [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) - Total investments: 10 - Last investment: Aug 2026 - Lead investor: 100% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/martin-heidecker-454b308 Martin Heidecker is a Series A investor at Boehringer Ingelheim Venture Fund focused on Biotechnology and Health Care. Martin Heidecker - Managing Director @ Boehringer Ingelheim Venture Fund ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Biotechnology | 8 | 80% | | Health Care | 6 | 60% | | Medical | 5 | 50% | | Therapeutics | 4 | 40% | | Pharmaceutical | 4 | 40% | 10 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series A | 4 | 40% | | Series C | 2 | 20% | | Seed | 1 | 10% | | Series B | 1 | 10% | | Series E | 1 | 10% | 6 stages tracked in total. ### Country | Country | Investments | Share | | --- | --- | --- | | United States | 8 | 80% | | Switzerland | 1 | 10% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | Vedanta Biosciences | Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $40M | Venture - Series Unknown | Aug 06, 2026 | | | Vedanta Biosciences | Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $106.5M | Series E | Apr 25, 2023 | | | BioVersys | Bioversys AG is a biopharmaceutical company located in Basel that focuses on research and development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and restore the efficacy of approved antibiotics. Their focus is on creating therapies to combat multidrug-resistant (MDR) bacterial infections, a major globalhealth issue. BioVersys’ proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform is designed to identify new treatments by inhibiting bacterial resistance mechanisms, thereby making antibiotics more effective. | $9M | Series C | Jan 05, 2023 | | | Venatorx Pharmaceuticals | Venatorx Pharmaceuticals is a private company that focuses on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. The company was founded in 2010 and is headquartered in Malvern, Pennsylvania. | $34M | Series C | Apr 04, 2022 | | | Adaptive Phage Therapeutics | Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria. Its services are provided using clinical and therapeutic technology that matches phages to patient-specific bacterial infections, enabling medical researchers to develop drugs that can detect and eliminate multi-drug resistantbacteria. | $20M | Series B | Apr 04, 2022 | | | Libra Therapeutics | Libra Therapeutics is a biotechnology company focused on developing novel disease-modifying therapeutics that can restore the cellular balance disrupted in neurodegenerative diseases. | $29M | Series A | Sep 23, 2020 | | | Rgenta Therapeutics | Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its leadprograms and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases.It was founded in 2018 and is headquartered in Cambridge, Massachusetts. | $20M | Seed | Apr 02, 2020 | | | Sentien Biotechnologies | Sentien Biotechnologies is a privately-owned, clinical-stage company developing novel cell therapies that restore balance to the immune system and transform treatment options for patients with systemic inflammatory diseases. The company's innovative blood conditioning approach has been proven to significantly enhance exposure and extendtherapeutic activity of Mesenchymal Stromal Cells (MSCs). By immobilizing MSCs in an extracorporeal device, their flagship SBI-101 product enables sustained, controlled dosage of secreted anti-inflammatory and regenerative properties that are unattainable by direct injection or intravenous infusion.Sentien Biotechnologies was established in 2008 and is headquartered in Lexington, Massachusetts, United States. | $12M | Series A | Apr 04, 2017 | | | Sentieon | Sentieon develops and commercializes cloud-based bio-informatics solutions for the life sciences and clinical market. They develop and supply a suite of bioinformatics secondary analysis tools that process genomics data with high computing efficiency, fast turnaround time, accuracy, and consistency. Some of the released products include SentieonDNAseq, a germline DNA pipeline; and Sentieon TNseq, for tumor-normal somatic variant detection. The company’s tools are scalable, deployable, upgradable, and software-only solutions. The Sentieon tools achieve their efficiency and consistency through optimized computing algorithm design and enterprise-strength software implementation.The company was founded by Jun Ye in 2014 and is headquartered in Mountain View, California. | $3.8M | Series A | Apr 04, 2014 | | | ArmaGen Technologies | ArmaGen is a developer of therapies designed to address neurological complications. The company's pipeline of innovative therapies penetrate the blood-brain barrier to treat neurological complications of many diseases, including lysosomal storage disorders (LSDs), Alzheimer's and Parkinson's, enabling patients suffering fromneurodegenerative disorders to get improved treatment. | $17M | Series A | Nov 29, 2012 | | 10 of 10 investments shown. ## Co-investors - [Mass Medical Angels](https://shizune.co/investors/profile/mass-medical-angels) — VC Fund, 2 deals together - [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 1 deal together - [Atlantic Neptune](https://shizune.co/investors/profile/atlantic-neptune) — VC Fund, 1 deal together - [AXA Investment Managers](https://shizune.co/investors/profile/axa-investment-managers) — VC Fund, 1 deal together - [Bill & Melinda Gates Foundation](https://shizune.co/investors/profile/bill-melinda-gates-foundation) — VC Fund, 1 deal together - [BioInnovation](https://shizune.co/investors/profile/bioinnovation) — VC Fund, 1 deal together ## About Boehringer Ingelheim Venture Fund VC Fund · Ingelheim Am Rhein, Germany Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies. 4 contacts available at Boehringer Ingelheim Venture Fund. | Name | Title | Profile | | --- | --- | --- | | Debbie Lin | Executive Director | https://shizune.co/investors/profile/debbie-w-lin | | Knut Elbers | Project Manager | https://shizune.co/investors/profile/knut-elbers | | Martin Heidecker | Managing Director | https://shizune.co/investors/profile/martin-heidecker | | Oliver Reuss | Executive Director and Investment Manager | https://shizune.co/investors/profile/oliver-reuss | ## Similar investors ### Similar stage - [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund ## FAQ ### What does Martin Heidecker invest in? Martin Heidecker invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series C stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did Martin Heidecker last invest? The most recent investment recorded for Martin Heidecker closed in Aug 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co